An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. - Wikidata - awgldk - TriplyDB

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

http://www.wikidata.org/entity/Q46913592

about

Hydroxyzine for generalised anxiety disorder Pregabalin for the treatment of generalized anxiety disorder: an update Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.Effectiveness of therapeutic massage for generalized anxiety disorder: a randomized controlled trial Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.Complementary medicine, exercise, meditation, diet, and lifestyle modification for anxiety disorders: a review of current evidence.Pregabalin for the management of fibromyalgia syndrome Pregabalin: a review of its use in adults with generalized anxiety disorder.Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.Pharmacotherapy of anxiety disorders: a critical review Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders.Post Hoc Analyses of Anxiety Measures in Adult Patients With Generalized Anxiety Disorder Treated With Vilazodone.Treatment of comorbid anxiety and autism spectrum disorders Does pregabalin have neuropsychotropic effects?: a short perspective.Combination of noninvasive brain stimulation with pharmacotherapy.Modulation of ion channels in clinical psychopharmacology: adults and younger people.Elucidating the mechanism of action of pregabalin: α(2)δ as a therapeutic target in anxiety.Agomelatine in treating generalized anxiety disorder.Role of atypical antipsychotics in the treatment of generalized anxiety disorder.Vintage treatments for PTSD: a reconsideration of tricyclic drugs.Efficacy and safety of pregabalin in generalised anxiety disorder: A critical review of the literature.Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD.Is the perceived placebo effect comparable between adults and children? A meta-regression analysis.Post hoc analysis of pregabalin vs. non-pregabalin treatment in patients with cancer-related neuropathic pain: better pain relief, sleep and physical health.A meta-analysis of the efficacy of pregabalin in the treatment of generalized anxiety disorder.[Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies].Pregabalin augmentation of antidepressants in older patients with comorbid depression and generalized anxiety disorder-an open-label study.The best next drug in the course of generalized anxiety disorders: the "PN-GAD-algorithm".The effects of single dose anxiolytic medication on the CO2 models of anxiety: differentiation of subjective and objective measures.Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials.The efficacy of benzodiazepines as acute anxiolytics in children: A meta-analysis.A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder.A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder.Community-deliverable exercise and anxiety in adults with arthritis and other rheumatic diseases: a systematic review with meta-analysis of randomised controlled trials.Lavender oil preparation Silexan is effective in generalized anxiety disorder--a randomized, double-blind comparison to placebo and paroxetine.Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.

P2860

Q24235649-57DB05C3-C44A-4750-A98C-C3EE16945E23 Q24604809-861C3B44-67B3-48DD-9C5F-D516EBB30B7F Q33734249-55BA8D22-BDC7-4111-9154-45A82869CF9B Q33798078-BC8FBD36-3D22-4A10-A0E3-9697B3610184 Q34024109-25D7EA93-0CF2-4C5E-A7B5-646096BA872B Q34070824-74A7ED16-13AF-4850-8D0B-54ACB6E3E765 Q34092254-B1FF89DE-67F3-4568-AFCB-B8CE5365713C Q34411930-5EC6213D-1E58-42BE-B8F1-E13EBE0B2F5B Q34418349-CDCF4652-A933-4BA1-AD20-ADE8711A3237 Q34434641-9063797E-335B-4D83-B71D-41AF0F341EF0 Q34500233-8851AE7C-F617-485C-9BBF-DE244C1D500C Q34672417-0F34B60F-E41C-43FA-8B45-541DFE9321C0 Q34865036-38BAC2E7-955A-49DB-A770-B268D1A50BDB Q35686859-E9971C3B-3046-41AF-9FAA-64B8FDD3D81D Q36205791-C0C08618-49BE-44C2-B17F-5B7624F29B65 Q37115879-3C6E628F-0ADB-4B1C-B4E7-B0189A95837C Q37257081-6F420F1B-5294-4322-9778-D09D9A31C8EB Q37484092-20F049D5-5B55-489D-A882-3D315EEE1859 Q37820973-42CE96AF-4692-47CD-A564-18412EF2E8BD Q37960095-FFD151BE-364E-4840-B255-60348E4F2093 Q38025453-C9D4178D-8C1B-428A-B053-D23E902CB992 Q38207149-456AF11D-9E84-4F73-AE92-9C8A21889F14 Q38209188-685D487E-0596-49F8-BCD4-95501C5D9105 Q38317410-E206E04D-C717-4C37-9852-4779CAF12937 Q38563874-D105BD6A-F075-4CDD-B3C1-C74F808E4526 Q38831882-86A976F0-0668-47FB-B4BF-29DC67A77EE2 Q38959593-D2865FFC-AF77-495D-A821-E3122810E6FC Q39260473-1BD0DB4D-C666-46F3-8883-65CEE42BCF86 Q39702488-F107EFF2-0D7A-41DF-A4B2-5C32128B7A78 Q42751572-48189950-2F62-41C7-9889-3C66D779486A Q43450686-F9B58313-D356-4323-92B3-C73EC6AEC89C Q45159165-D752ED65-A234-4D9A-A2B8-8D6EF2B56871 Q46334050-BE41376B-CCAB-49F1-A3A0-CA0BDAE94007 Q47576191-25747646-AFB3-4ABA-8ACF-8E37948BF800 Q47870475-8129A5FE-7453-4325-860B-B9F8BDE25055 Q48371140-C5FD493E-EC57-498D-96FB-09634AFF008F Q48386112-A6A4BCB7-336A-430B-8876-7F2430C75E7F Q49893463-93B9A91F-7AF3-4332-B8A2-F5D622D018BB Q50663949-29696EE3-76E0-46A9-88D9-01C23DAC0DBD Q53091817-151EE907-6D9F-4AF8-849F-A77F814F01E5

P2860

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

http://www.wikidata.org/entity/Q46913592

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

@en

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

@nl

type

label

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

@en

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

@nl

prefLabel

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

@en

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

@nl

P1433

Q46913592-C2D10B64-587C-4EC5-8543-7B9E81C1402F

P1476

Q46913592-D33B2403-B98A-4E5D-AE64-1E7523AA413A

P2093

Q46913592-6A8ECAE1-445B-4BCB-95EF-8386F890FF74

Q46913592-AC9E0132-6ED8-46F7-8763-3371B744B0D2

Q46913592-BA219B63-BEF9-4130-8FB9-B8FDDB539AB9

P2860

Q46913592-08557668-1C18-44CE-B833-529E06FF78DE

Q46913592-09CA55DD-8D34-435D-9DA5-F97CCDD2C1FB

Q46913592-18E74B57-672A-4AE0-AD5D-0BB0CBA46350

Q46913592-2AE4245E-FCCB-4ADA-9E97-56C4D810F2E3

Q46913592-2B50CA8F-9D56-4770-842E-871D183BFA47

Q46913592-2BD1A510-41D0-4A6C-B988-042D013DC2AA

Q46913592-312375CC-384C-49BB-AD4C-4996A3D6D9FB

Q46913592-3981924D-78A7-4C3C-B3FD-A6BA22687882

Q46913592-497504AC-A8D7-4189-BC5D-54A259A35890

Q46913592-4C324594-3F53-402F-B2C9-1DA0D473AFED

P304

Q46913592-7E00D092-F6E9-46F9-A587-5C8140329540

P31

Q46913592-1a090a49-6f87-42c1-8d64-b25b5a2d30e6

Q46913592-B2F7F243-FBA8-451A-B180-47905E8CFBE5

P356

Q46913592-1CEE058B-EF8B-4A14-881F-BF4FBD4D79B2

P407

Q46913592-BCC17B98-09A8-493E-A37C-76A76A299E8F

P433

Q46913592-502FBF34-B7F4-414F-9C03-B4F708984877

P478

Q46913592-6A4FDF9F-CFC2-4C83-B181-BB492C159895

P577

Q46913592-2A2AB7D9-115A-4893-850C-50E56C1EA948

P5875

Q46913592-91CB22DC-7DE0-4CB0-93B1-0A93F0B10747

P698

Q46913592-E525DA83-D169-4B54-AB1E-E6A6772EB06C

P921

Q46913592-49B62F41-64FF-4FFA-8AB1-EB0DAF064412

P356

0269881107076996

P1433

Journal of Psychopharmacology

P1476

An effect-size analysis of pharmacologic treatments for generalized anxiety disorder.

@en

P2093

Jonathan R T Davidson

http://www.w3.org/2001/XMLSchema#string

Larry A Tupler

http://www.w3.org/2001/XMLSchema#string

Rosario B Hidalgo

http://www.w3.org/2001/XMLSchema#string

P2860

Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group

The assessment of anxiety states by rating

Efficacy of kava extract for treating anxiety: systematic review and meta-analysis.

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database.

Placebo response in studies of major depression: variable, substantial, and growing.

Generalized anxiety disorder. An important clinical concern.

Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis.

Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.

Efficacy of sertraline in a 12-week trial for generalized anxiety disorder.

A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder.

P304

864-872

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0269881107076996

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2007-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5862844

http://www.w3.org/2001/XMLSchema#string

P698

17984162

http://www.w3.org/2001/XMLSchema#string

P921